Ország: Európai Unió
Nyelv: román
Forrás: EMA (European Medicines Agency)
Tafasitamab
Incyte Biosciences Distribution B.V.
L01FX12
tafasitamab
Agenți antineoplazici
Lymphoma, Large B-Cell, Diffuse
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Revision: 4
Autorizat
2021-08-26
The website encountered an unexpected error. Try again later.
Olvassa el a teljes dokumentumot
The website encountered an unexpected error. Try again later.
Olvassa el a teljes dokumentumot